Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/460)
-
Publication number: 20150119414Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.Type: ApplicationFiled: January 2, 2015Publication date: April 30, 2015Applicant: PIVOTAL THERAPEUTICS INC.Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar Ahmad SHAIKH, Jason YANTHA, Valerie B. SCHINI-KERTH
-
Publication number: 20150110871Abstract: The present invention relates to a gastric retentive tablet composition comprising: (1) coated particles essentially consisting of a drug and an amino methacrylate copolymer, (2) a methacrylic acid copolymer and (3) an excipient, wherein items 1, 2, and 3 are blended together, and then compressed into a gastric retentive tablet. Thus, the coated particles (item 1), a methacrylic acid copolymer and the excipient are evenly distributed in the tablet. The excipient is selected from a group consisting of a retarding agent, a binder, a filler, a chelating agent, a diluent, a disintegrant, a lubricant, a colorant, a solubilizing agent, or a mixture thereof. The coated particles (item 1) do not contain methacrylic acid polymer.Type: ApplicationFiled: January 3, 2015Publication date: April 23, 2015Inventor: David Wong
-
Publication number: 20150104504Abstract: The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms.Type: ApplicationFiled: May 7, 2013Publication date: April 16, 2015Inventors: Bernardus Machielse, Timothy J. Maines, Michael H. Davidson, Bharat M. Mehta
-
Patent number: 9006468Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.Type: GrantFiled: January 25, 2012Date of Patent: April 14, 2015Assignee: Dow AgroSciences, LLC.Inventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
-
Publication number: 20150094323Abstract: Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are provided.Type: ApplicationFiled: December 8, 2014Publication date: April 2, 2015Inventor: Susanne Riel
-
Publication number: 20150094322Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.Type: ApplicationFiled: December 8, 2014Publication date: April 2, 2015Inventor: Susanne Riel
-
Publication number: 20150080463Abstract: Methods are provided for diagnosing the risk of a cardiovascular event in a patient. In some embodiments, the method includes measuring the level of proprotein convertase subtilisin kexin type 9 (PCSK9) in a sample obtained from a patient and comparing the measured level of PCSK9 to a control. Also provided are methods of selecting a therapy for a patient prior to administration of the therapy. In some embodiments, the method includes measuring a PCSK9 blood concentration in a sample from a patient to determine the presence or absence of a PCSK9 blood concentration indicative of responsiveness to an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Further provided are methods for assessing the efficacy of a therapy being administered to a patient. In certain embodiments, the method includes detecting a change in a PCSK9 blood concentration in a sample from a patient, wherein a change in detected levels is indicative of whether the therapy is efficacious.Type: ApplicationFiled: March 16, 2011Publication date: March 19, 2015Applicant: BG MEDICINE, INC.Inventor: Pieter Muntendam
-
Publication number: 20150065567Abstract: Administration of certain 1-phenylalkanecarboxylic acid derivatives is useful for treating, preventing and/or reducing the risk of developing Alzheimer's Disease and multiple sclerosis.Type: ApplicationFiled: August 15, 2014Publication date: March 5, 2015Applicant: Chiesi Farmaceutici S.p.A.Inventors: Bruno Imbimbo, Marina Pizzi, Daniel Chain
-
Patent number: 8969397Abstract: Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment pain by inhibiting the NF?B family of transcription factors.Type: GrantFiled: February 5, 2010Date of Patent: March 3, 2015Assignee: Warsaw Orthopedic, Inc.Inventors: Eric N. Burright, Lisa L. Shafer, Bill McKay, John Zanella
-
Patent number: 8969390Abstract: The invention relates to liquid compositions which contain a) from 40 to 99.9% by weight of sorbitan monocaprylate and b) from 0.1 to 60% by weight of one or more antimicrobial substances selected from the group consisting of the components b1) to b5): b1) specific organic acids and the salts thereof, b2) specific formaldehyde donors, b3) specific isothiazolinones, b4) specific paraben esters and the salts thereof, and b5) specific pyridones and the salts thereof. The liquid compositions are suitable for the production of cosmetic, dermatological or pharmaceutical products.Type: GrantFiled: May 11, 2010Date of Patent: March 3, 2015Assignee: Clariant Finance (BVI) LimitedInventors: Peter Klug, Sonja Gehm, Guiseppina Kluth, Franz-Xaver Scherl, Maurice Frederic Pilz
-
Publication number: 20150051235Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: October 21, 2014Publication date: February 19, 2015Applicant: Infirst Healthcare LimitedInventors: Robin Mark Bannister, John Brew, Suzanne Jane Dilly, Gregory Alan Stoloff, Wilson Caparros-Wanderley
-
Publication number: 20150051256Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.Type: ApplicationFiled: October 28, 2014Publication date: February 19, 2015Applicant: Takeda Pharmaceutical Company LimitedInventor: Naomi Kitamoto
-
Publication number: 20150051276Abstract: Compounds are used as agents that deter feeding of crops by agricultural pests such as hemiptera, lepidoptera and coleoptera, including, but not limited to, stink bugs, codling moth larvae and granary weevils.Type: ApplicationFiled: April 30, 2013Publication date: February 19, 2015Inventor: Robert H. Bedoukian
-
Publication number: 20150045424Abstract: It is described the use of L-carnitine and/or an alkanoyl L-carnitine, or a pharmaceutically acceptable salt thereof, in combination with a statin, for the preparation of a medicament for the treatment of type 2 diabetes.Type: ApplicationFiled: October 28, 2014Publication date: February 12, 2015Inventors: Franco GAETANI, Ashraf VIRMANI
-
Patent number: 8946457Abstract: Flavone derivatives, preparative method of the derivatives and use thereof as medicaments for treating diabetes. The structure of the derivatives is presented by formula 1: In the structure, R1 and R2, which are identical or not, represent hydrogen atom, halogen, cyano, hydroxyl, trifluoromethyl, thio-methyl, benzyloxy. C1-C8 linear chain or branch chain alkyl, C1-C8 linear chain or branch chain alkoxy. The pharmacological test indicates that the flavone derivatives can significantly increase the glucose consumption of Hep-G2 cell with insulin resistance activity, promote translocation of glucose transporter 4 of skeletal muscle cells (L6GLUT4myc) at different level, and significantly increase glucose intake and utilization by cells.Type: GrantFiled: November 12, 2010Date of Patent: February 3, 2015Assignee: Tianjin Medical UniversityInventors: Hongquan Duan, Nan Qin, Wenyan Niu, Meina Jin, Lihuan Shi, Ying Chen
-
Patent number: 8940911Abstract: A library of unnatural squarylated homoserine lactones (SHLs) and squarylated lactones that bear potential to modulate biofilm formation in Gram negative bacteria. At low concentrations (˜200 ?M), these small molecules inhibit biofilm formation of E. coli. Moreover, these compounds are not toxic up to 300 ?M and do not significantly attenuate E. coli growth. The SHLs have potential to disperse established biofilm and demonstrate an enhanced reduction (˜50%) of the maximum biofilm thickness by use of SHLs during biofilm growth.Type: GrantFiled: August 1, 2013Date of Patent: January 27, 2015Assignee: Syracuse UniversityInventors: Yan-Yeung Luk, Sri Kamesh Narasimhan, Eric Falcone
-
Publication number: 20150025069Abstract: This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.Type: ApplicationFiled: October 3, 2014Publication date: January 22, 2015Inventors: Timothy Scott Daynard, Geoffrey C. Winters, David W.C. Hunt
-
Publication number: 20150025134Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: ApplicationFiled: October 9, 2014Publication date: January 22, 2015Inventor: Thomas Najarian
-
Publication number: 20150023868Abstract: The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.Type: ApplicationFiled: February 21, 2014Publication date: January 22, 2015Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Othon Iliopoulos, Michael Zimmer
-
Publication number: 20150018378Abstract: The present invention relates methods to increase the expression of fatty acid desaturases (FADS) and increase cellular and tissue levels of highly unsaturated fatty acids (HUFA) by modulating one or more of the FADS via the action of specific classes of drugs (e.g., statins and LXR agonists). The present invention also relates to methods of treating conditions (e.g., tumor and cancer) involving deficient function of FADS by administering statins and/or LXR agonists. The present invention further relates to methods of determining the need for statins or dietary LCPUFA in subjects.Type: ApplicationFiled: January 28, 2013Publication date: January 15, 2015Inventors: James Thomas Brenna, Holly Turner Reardon, Sesha Durga Kumar Kothapalli
-
Publication number: 20150011525Abstract: A stable ternary solid dispersion composition with enhanced physical stability and/or bioavailability comprising: (a) about 1% wt. to about 50% wt. of one or more poorly soluble active pharmaceutical ingredient (API) which belongs to Biopharmaceutics Classification System (BCS) class II and/or IV; (b) about 11% wt. to about 50% wt. of at least one water-soluble polymer; and (c) about 20% wt. to about 99% wt. of crosslinked polyvinylpyrrolidone (crospovidone, a water-insoluble polymer). The solid dispersion is capable of inhibiting crystallization of API in solid state and/or aqueous gastrointestinal tract (GIT) medium. Also disclosed is a method of preparation of such solid dispersion composition by fusion or solvent or fusion-solvent method.Type: ApplicationFiled: September 13, 2012Publication date: January 8, 2015Applicant: ISP Investments Inc.Inventors: Yunxia Bi, Mohammed Abdul Rahman, James David Lester
-
Publication number: 20150010469Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer, stereoisomer or deuterated analogue thereof, wherein X, R, R1, R2, R3, R4, M1, M2, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: July 3, 2014Publication date: January 8, 2015Applicants: British Columbia Cancer Agency Branch, University of British ColumbiaInventors: Raymond John Andersen, Javier Garcia Fernandez, Marianne Dorothy Sadar
-
Patent number: 8927599Abstract: The use of statins as antiepileptic, anticonvulsant, neuroprotector and antioxidant compounds, potentially useful for the prevention and/or treatment of epilepsy, epileptic seizures, convulsions, neurodegenerative diseases, or diseases associated with undesired oxidation, is described.Type: GrantFiled: June 3, 2009Date of Patent: January 6, 2015Assignee: Neuron Biopharma, S.A.Inventors: Javier Santos Burgos Muñoz, Carlos Ramirez Moreno, Javier Velasco Alvarez
-
Publication number: 20150005351Abstract: Methods are disclosed for determining a patient's risk for developing Alzheimer's disease and preventing or treating Alzheimer's disease. Kits for assessing a patient's risk of developing Alzheimer's are also provided.Type: ApplicationFiled: June 26, 2014Publication date: January 1, 2015Inventors: Salvador Soriano, Michael Castello
-
Patent number: 8921320Abstract: A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium, potassium-adenosine triphosphatase (Na+, K+-ATPase) that is then followed by an activation of VGSCs, for example, by electrical or pharmacological stimulation. Activation of VGSCs conducts sodium into the cancer cells in much greater amounts than non-cancer cells. Water follows this sodium gradient into the cancer cells, causing swelling and lysis. Because non-cancerous cells do not over-express VGSCs, less sodium and less water will enter the cells, and the non-cancerous cells will not lyse. This method is applicable to all cells that over-express VGSCs, including, but not limited to, highly invasive breast cancer, prostate cancer, small cell lung cancer, non-small cell lung carcinoma, lymphoma, mesothelioma, neuroblastoma, and cervical cancer.Type: GrantFiled: July 19, 2012Date of Patent: December 30, 2014Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Dennis J. Paul, Harry J. Gould
-
Publication number: 20140374516Abstract: Disclosed is a process for the preparation of drug/carrier inclusion composites which involves co-grinding the mixture of drug and carrier powders in a fluid-jet mill, in particular one using air or nitrogen as the fluid, which is suitably modified to allow mechanical fusion of the powders.Type: ApplicationFiled: January 25, 2013Publication date: December 25, 2014Applicant: MICRO-MACINAZIONE S.A.Inventors: Fabio Carli, Piero Iamartino, Milko Leone
-
Patent number: 8916717Abstract: The invention relates to dioxaspiroketal derivatives of formula (I): wherein R, is selected from the group consisting of H, straight or branched chain C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, cycloalkyl, heterocyclyl, phenyl, optionally para-, meta- or ortho-substituted with 0 to 3 substituent selected from halogen, —CN, —NH2, —OH, —NO2, COOR2, wherein R2 is selected from H and C1-C6 alkyl, n is 1 or 2, X is O or S, R1 is selected from H, OH, halogen, C1-C6 alkyl, C1-C6 alkoxy, COOR3, wherein R3 is selected from H and C1-C6 alkyl, or physiologically acceptable salts thereof, process for preparation thereof, their uses in medical field, in particular as anti-tumor medicaments.Type: GrantFiled: May 10, 2007Date of Patent: December 23, 2014Assignee: Consiglio Nazionale Delle RicercheInventors: Antonella DeMico, Andrea Cottarelli, Mariapia Fuggetta, Giulia Lanzilli, Maria Tricarico
-
Publication number: 20140371134Abstract: In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent.Type: ApplicationFiled: June 18, 2013Publication date: December 18, 2014Inventor: Jay Richard Ray, II
-
Publication number: 20140371285Abstract: Salinomycin analogs and pharmaceutically acceptable compositions containing salinomycin analogs. Dosage forms and kits comprising salinomycin analogs and pharmaceutically acceptable compositions containing salinomycin analogs. Methods of using salinomycin analogs, pharmaceutically acceptable compositions, dosage forms, and kits for the treatment of proliferative diseases, e.g.Type: ApplicationFiled: January 7, 2013Publication date: December 18, 2014Inventors: Kevin Sprott, Michael Lewis, Hyeongwook Choi, Frank Fang, Mingde Shan, Tsvetelina I. Lazarova, Lin Li, M. Arshad Siddiqui, Robin Larouche-Gauthier, Alexandre Lemire
-
Publication number: 20140370060Abstract: The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum-producing tissue.Type: ApplicationFiled: February 1, 2013Publication date: December 18, 2014Inventors: Kenneth Gek-Jin Ooi, Stephanie Louise Watson
-
Publication number: 20140371305Abstract: An antibiotic inhalation or irrigation composition for the treatment of bacterial infections especially in the respiratory tract, is provided. The antibiotic inhalation or irrigation composition may include a mixture of mupirocin as active pharmaceutical ingredient (API), and a micronized poloxamer composition as excipient. Micronized poloxamer composition may be produced by mixing poloxamer 188 and poloxamer 407 in an apparatus where a low-frequency acoustic field is applied to facilitate mixing. Antibiotic inhalation or irrigation composition may be obtained in powder or solution form. In other embodiments, antibiotic inhalation or irrigation composition may be employed to produce a topical formulation for the treatment of traumatic skin lesions. In some embodiments, other suitable poloxamers or sugar alcohols may be employed as excipients.Type: ApplicationFiled: June 14, 2013Publication date: December 18, 2014Applicant: PROFESSIONAL COMPOUNDING CENTERS OF AMERICAInventor: Daniel Banov
-
Publication number: 20140336248Abstract: Aqueous compositions comprising salinomycin, or a pharmaceutically acceptable salt thereof, miscible organic solvents, and solubilizers and/or emulsifying agents are disclosed. The formulations disclosed herein are useful in the treatment of cancer, especially cancers associated with cancer stem cells or cancerous mesenchymal cells. The method of treating a subject may further comprise identifying a subject having a disorder suitable for treatment with the aqueous compositions described, comprising detecting one or more biomarkers predictive of the prevalence of a cancer having or enriched for cancer stem cells (CSCs).Type: ApplicationFiled: December 5, 2012Publication date: November 13, 2014Inventors: Wendi Ma, Peter Elliott, Mahesh Padval
-
Publication number: 20140328936Abstract: The invention relates to a pharmaceutical composition, comprising or consisting of: 10 to 30 weight percent of at least a pharmaceutically active amount of a pharmaceutical substance selected from the group comprising statins, in particular water-insoluble, oxidatively degradable statins, preferably cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combinations thereof, 30 to 70 weight percent of lactose hydrate, 2 to 15 weight percent of microcrystalline cellulose, 5 to 25 weight percent of a partially water-soluble starch, 0.2 to 4 weight percent of at least one alkali and/or alkaline-earth salt of stearic acid and/or stearyl fumaric acid, wherein the composition contains no antioxidatively active substances such as chain terminators, reductants, free-radical scavengers, and complexing agents.Type: ApplicationFiled: December 6, 2012Publication date: November 6, 2014Applicant: HEXAL AGInventors: Theresa Taeubrich, Patrick Rother
-
Patent number: 8877715Abstract: There is provided a series of novel neuropeptide Y-cytotoxic conjugates, compositions comprising the same, and methods relating to their therapeutic use for the treatment of disease or condition states associated with aberrant or undesirable proliferation of cells that express NPY-Y1 receptors.Type: GrantFiled: August 18, 2011Date of Patent: November 4, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Kevin Zhou, Daniel B. Deoliveira
-
Patent number: 8877754Abstract: The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.Type: GrantFiled: August 17, 2011Date of Patent: November 4, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Gerald Juergen Roth, Martin Fleck, Heike Neubauer, Bernd Nosse
-
Publication number: 20140323561Abstract: Control and repellency of biting flies, house flies, ticks, ants, fleas, biting midges, cockroaches, spiders and stink bugs is obtained by contact of the insects with at least one of the compounds of the structure (I).Type: ApplicationFiled: October 21, 2013Publication date: October 30, 2014Inventor: Robert H. Bedoukian
-
Patent number: 8871800Abstract: Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.Type: GrantFiled: September 17, 2009Date of Patent: October 28, 2014Assignee: GlaxoSmithKline, LLCInventors: Roelof M. L. Rongen, Robert A. Shalwitz, Douglas Kling, Ralph T. Doyle, Jr.
-
Publication number: 20140314847Abstract: The present invention provides a controlled release oral pharmaceutical composition having a therapeutically effective amount of one or more pharmacologically active agent having low bioavailability; one or more solubilizers; one or more biocompatible swelling agents; and a swelling enhancer. The swelling agent, in combination with swelling enhancer, swells in the presence of water in gastric fluid such that the size of the dosage form is sufficiently increased to provide retention of the dosage form in the stomach of a patient, which gradually erodes within the gastrointestinal tract over a prolonged time period.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Pratibha S. PILGAONKAR, Maharukh T. RUSTOMJEE, Anilkumar S. GANDHI, Pradnya M. BAGDE
-
Publication number: 20140309295Abstract: The present invention describes a compound of formula (I) its hydroxy acid form, the pharmaceutically acceptable salts of said hydroxy acid and pharmaceutically acceptable prodrugs and solvates of the compound and of its hydroxy acid form and, in particular, said compound, its hydroxy acid form, salts, etc. for its use in the prevention of: neurodegenerative diseases, cognitive deterioration, diseases associated with undesired oxidation, age-associated pathological processes and progeria, epilepsy, epileptic seizures and convulsions, cardiovascular diseases such as atherosclerosis, atrial fibrillation, dyslipemia, hypercholesterolemia, hyperlipidemia, and hypertriglyceridemia, or fungal or viral infections.Type: ApplicationFiled: June 25, 2014Publication date: October 16, 2014Inventors: Javier Santos BURGOS MUÑOZ, José Luis ADRIO FONDEVILA, Maria del Carmen RAMOS MARTÍN, Saleta SIERRA ÁVILA, Juan Maria ALFARO SÁNCHEZ, Carlos RAMÍREZ MORENO, Sonia CAMPOY GARCIA, Javier VELASCO ALVAREZ, Ángel RUMBERO SÁNCHEZ
-
Patent number: 8858994Abstract: The present invention relates to novel formulations comprising ezetimibe as active ingredient. In particular the invention relates to a pharmaceutical composition comprising 5 to 20 wt-% ezetimibe, 50 to 85 wt-% diluent, 3 to 25 wt-% disintegrant, 1 to 10 wt-% binder, and 0.5 to 1 wt-% lubricant, characterized in that the ezetimibe has a particle size distribution of d(0.9) of 5 ?m to 35 ?m and d(0.5) of 3 ?m to 20 ?m, as well as methods for preparing said formulations.Type: GrantFiled: December 9, 2008Date of Patent: October 14, 2014Assignee: Ratiopharm GmbHInventors: Ganesh Gat, Pasupuleti Giridhara Rao, Javed Hussain
-
Patent number: 8853256Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.Type: GrantFiled: May 31, 2007Date of Patent: October 7, 2014Assignee: Mochida Pharmaceutical Co., Ltd.Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
-
Patent number: 8853229Abstract: A combination is described comprising at least one omega-3 fatty acid, optionally esterified or salified, at least one statin, Coenzyme Q10, resveratrol, at least one policosanol, pantethine, selenium, and zinc. This combination is endowed with a synergistic effect and is useful in the treatment of disease forms due to insulin resistance and in cardiovascular diseases.Type: GrantFiled: July 19, 2005Date of Patent: October 7, 2014Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Claudio Cavazza
-
Publication number: 20140294995Abstract: The present invention relates to a pharmaceutical formulation containing a combination of (a) at least one astringent active substance and (b) at least one mucilaginous drug and the use thereof for the prevention or treatment of inflammatory diseases of the oropharyngeal region and for the treatment of painful irritations of the mucosa in the oropharyngeal region and associated irritable cough.Type: ApplicationFiled: April 1, 2014Publication date: October 2, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Julia BONI, Bernd PLOHMANN, Sandra SAUERLAND
-
Publication number: 20140296240Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: June 17, 2014Publication date: October 2, 2014Inventors: Gary Mark COPPOLA, Yuki IWAKI, Rajeshri Ganesh KARKI, Toshio KAWANAMI, Gary Michael KSANDER, Muneto MOGI, Robert SUN
-
Publication number: 20140286931Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Inventor: Chengzhi Zhang
-
Patent number: 8828450Abstract: The present invention relates to a composition for use against one or more pathogens, comprising at least one antagonistic micro-organism and at least one salt and/or derivatives thereof as defined in claim 1. The present invention further relates to said composition for use as biopesticide.Type: GrantFiled: September 23, 2005Date of Patent: September 9, 2014Assignee: BionextInventors: Philippe Pujos, Mohamed Haïssam Jijakli
-
Publication number: 20140248223Abstract: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain at least one active agent, which may be administered to a user topically, transmucosally, vaginally, ocularly, aurally, nasally, transdermally or orally.Type: ApplicationFiled: March 3, 2014Publication date: September 4, 2014Applicant: MONOSOL RX, LLCInventors: Garry L. Myers, Richard C. Fuisz
-
Patent number: 8821932Abstract: A process for the production of a composition comprising a water-insoluble statin which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble statin ii) a water soluble carrier, iii) a solvent for each of the statin and the carrier, and b) spray-drying the mixture to remove the or each solvent and obtain a substantially solvent-free nano-dispersion of the statin in the carrier.Type: GrantFiled: June 29, 2007Date of Patent: September 2, 2014Inventors: David John Duncalf, Alison Jayne Foster, James Long, Steven Paul Rannard, Dong Wang
-
Publication number: 20140235636Abstract: The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicants: Cardioxyl Pharmaceuticals, Inc., The Johns Hopkins UniversityInventors: John P. Toscano, Art Sutton, Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost
-
Publication number: 20140235605Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.Type: ApplicationFiled: March 15, 2013Publication date: August 21, 2014Applicant: CELERA CORPORATIONInventor: CELERA CORPORATION